Masese Linnet, Baeten Jared M, Richardson Barbra A, Bukusi Elizabeth, John-Stewart Grace, Graham Susan M, Shafi Juma, Kiarie James, Overbaugh Julie, McClelland R Scott
aDepartment of Epidemiology bDepartment of Medicine cDepartment of Global Health dDepartment of Biostatistics eDepartment of Pediatrics, University of Washington, Seattle fVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA gDepartment of Obstetrics and Gynecology hDepartment of Medical Microbiology, University of Nairobi iKenya Medical Research Institute, Nairobi, Kenya jHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA kInstitute of Tropical and Infectious Diseases, University of Nairobi, Nairobi, Kenya.
AIDS. 2015 Jun 1;29(9):1077-85. doi: 10.1097/QAD.0000000000000646.
OBJECTIVE: The objective of this study was to understand temporal trends in the contribution of different genital tract infections to HIV incidence over 20 years of follow-up in a cohort of high-risk women. DESIGN: A prospective cohort study. METHODS: We performed monthly evaluations for HIV, vaginal yeast, bacterial vaginosis, Trichomonas vaginalis, Neisseria gonorrhoeae, nonspecific cervicitis, herpes simplex virus type two (HSV-2), genital ulcer disease (GUD) and genital warts. We used Cox regression to evaluate the association between sexually transmitted infections (STIs) and HIV acquisition over four time periods (1993-1997, 1998-2002, 2003-2007, 2008-2012). Models were adjusted for age, workplace, sexual risk behaviour, hormonal contraceptive use and other STIs. The resulting hazard ratios were used to calculate population attributable risk percentage (PAR%). RESULTS: Between 1993 and 2012, 1964 women contributed 6135 person-years of follow-up. The overall PAR% for each infection was prevalent HSV-2 (48.3%), incident HSV-2 (4.5%), bacterial vaginosis (15.1%), intermediate microbiota (7.5%), vaginal yeast (6.4%), T. vaginalis (1.1%), N. gonorrhoeae (0.9%), nonspecific cervicitis (0.7%), GUD (0.8%) and genital warts (-0.2%). Across the four time periods, the PAR% for prevalent HSV-2 (40.4%, 61.8%, 58.4%, 48.3%) and bacterial vaginosis (17.1%, 19.5%, 14.7%, 17.1%) remained relatively high and had no significant trend for change over time. The PAR% for trichomoniasis, gonorrhoea, GUD and genital warts remained less than 3% across the four periods. CONCLUSION: Bacterial vaginosis and HSV-2 have consistently been the largest contributors to HIV acquisition risk in the Mombasa Cohort over the past 20 years. Interventions that prevent these conditions would benefit women's health and could reduce their risk of becoming infected with HIV.
Cancer Causes Control. 2022-12
Nat Microbiol. 2022-8
Clin Obstet Gynecol. 2021-9-1
Antimicrob Agents Chemother. 2013-12
N Engl J Med. 2012-7-11
N Engl J Med. 2012-1-5
N Engl J Med. 2011-7-18
Curr Opin HIV AIDS. 2010-7